Abstract Background Identifying gaps in services that limit clinical care is essential to improve outcomes for children with central nervous system (CNS) tumors. The PediAtric Neuro-Oncology seRvices AssessMent Aid (PANORAMA), a comprehensive service evaluation tool, was used to assess pediatric neuro-oncology capacity across low- and middle-income countries (LMICs). Methods We conducted an assessment of institutions in LMICs between October 2025 and January 2026 using PANORAMA, which comprises 322 questions spanning the continuum of pediatric neuro-oncology care. Results A total of 34 institutions in 21 countries participated, located in Asia (47.1%), Africa (26.5%), Latin America (23.5%), and Europe (2.9%), and representing upper-middle-income (47.1%), lower-middle-income (47.1%), and low-income (5.9%) countries. Participating institutions included general (35.3%), oncology (26.5%), pediatric oncology (17.7%), and pediatric (17.7%) hospitals. The mean annual number of new CNS tumor cases was 70. Nineteen institutions (55.9%) had an established referral network. Specialist availability varied: 88.2% reported access to a neurosurgeon, 64.7% to a pediatric neurosurgeon, 97.1% to a pediatric oncologist, 67.7% to a pediatric neuro-oncologist, 82.4% to a radiation oncologist, 58.8% to a pediatric radiation oncologist, 100% to a pathologist, and 55.9% to a neuropathologist. Thirty institutions (88.2%) had a multidisciplinary team that met regularly to discuss patient management. Twenty-eight institutions (82.4%) had access to MRI, with 78.8% reporting turnaround times of 2–7 days. Seven (20.6%) institutions had access to methylation profiling. Nineteen (55.9%) centers were able to perform autologous bone marrow transplantation. Five (14.7%) institutions reported that fewer than 75% of patients with medulloblastoma initiated curative-intent treatment. Conclusions Pediatric neuro-oncology resources across LMICs are heterogeneous. While most institutions reported access to core services, significant gaps persist, particularly in advanced diagnostics and treatment delivery. These findings provide a foundation to inform priority setting and support the development of interventions to improve outcomes for children with CNS tumors.
Licona et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: